论文部分内容阅读
吉非替尼(gefitinib,1),化学名为N-(3-氯-4-氟苯基)-7-甲氧基-6-[3-(4-吗啉基)丙氧基]喹唑啉-4-胺,是英国AStraZeneca公司研发的表皮生长因子受体(EGFR)酪氨酸激酶抑制剂,于2002年首次在日本上市,2003年5月在美国及澳大利
Gefitinib (1) with chemical name N- (3-chloro-4-fluorophenyl) -7- methoxy- 6- [3- (4- morpholinyl) propoxy] Oxazoline-4-amine, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor developed by the British company AStraZeneca, was first marketed in Japan in 2002 and in May 2003 in the United States and Australia